New hope for Hard-to-Treat cancers: drug targets KRAS G12D mutation
NCT ID NCT05533463
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HRS-4642 in 102 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must have tried other treatments and have at least one measurable tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-4642 (a drug that targets the KRAS G12D mutation)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers that have a specific KRAS G12D mutation.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not prove safe or effective. Only 102 participants are enrolled, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.